{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:21:51Z","timestamp":1788459711338,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.toxicon.2026.109250","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:12:40Z","timestamp":1785424360000},"page":"109250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From uniformity to individuality: Computational modelling provides a mechanistic rationale for weight-adjusted botulinum neurotoxin a dosing"],"prefix":"10.1016","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-8338","authenticated-orcid":false,"given":"Eqram","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinitha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2082-2799","authenticated-orcid":false,"given":"Munim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam","family":"Saklayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9260-8032","authenticated-orcid":false,"given":"Istiaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohidus Samad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5801-2105","authenticated-orcid":false,"given":"John H.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-626X","authenticated-orcid":false,"given":"William Richard","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2026.109250_bib1","article-title":"Long term outcome for onabotulinumtoxinA (botox) therapy in chronic migraine: a 2-year prospective follow-up audit of patients attending the hull (UK) migraine clinic","volume":"4","author":"Ahmed","year":"2021","journal-title":"Cephalalgia Rep"},{"key":"10.1016\/j.toxicon.2026.109250_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2026.109250_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202305326","article-title":"Botulinum neurotoxin induces neurotoxic microglia mediated by exogenous inflammatory responses","volume":"11","author":"Ambrin","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.toxicon.2026.109250_bib4","doi-asserted-by":"crossref","DOI":"10.2147\/CCID.S138274","article-title":"Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone","volume":"10","author":"Anido","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.toxicon.2026.109250_bib5","article-title":"International consensus recommendations on the aesthetic usage of botulinum toxin type A (speywood unit) - part I: upper facial wrinkles","volume":"24","author":"Ascher","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.toxicon.2026.109250_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.toxicon.2026.109250_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2026.109250_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-015-1384-6","article-title":"High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis","volume":"122","author":"Baricich","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2026.109250_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-022-01710-x","article-title":"Introducing the FAIR principles for research software","volume":"9","author":"Barker","year":"2022","journal-title":"Sci. Data"},{"key":"10.1016\/j.toxicon.2026.109250_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/PHM.0000000000002410","article-title":"Safety and real-world dosing of OnabotulinumtoxinA for the treatment of adult spasticity post hoc analysis of the adult spasticity international registry study","volume":"103","author":"Bavikatte","year":"2024","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2026.109250_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2021.11.023","article-title":"Treatment of patients with upper limb and lower limb spasticity with OnabotulinumtoxinA in the adult spasticity international registry (ASPIRE)","volume":"214","author":"Bavikatte","year":"2022","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/head.13823","article-title":"Modifications to the PREEMPT protocol for OnabotulinumtoxinA injections for chronic migraine in clinical practice","volume":"60","author":"Begasse de Dhaem","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2026.109250_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2026.109250_bib14","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.toxicon.2026.109250_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/toxins16060266","article-title":"Update on non-interchangeability of botulinum neurotoxin products","volume":"16","author":"Brin","year":"2024","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-016-0436-x","article-title":"Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade?","volume":"56","author":"Calvier","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxicon.2026.109250_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050114","article-title":"Equity in vaccine trials for higher weight people? Protocol for a rapid review of inclusion and exclusion criteria for higher weight people in clinical trials for COVID-19","volume":"11","author":"Campbell","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.toxicon.2026.109250_bib18","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: a probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.toxicon.2026.109250_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxina for the treatment of crows feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000000704","article-title":"Repeated OnabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/01.PRS.0000144795.76040.D3","article-title":"Consensus recommendations on the use of botulinum toxin type A in facial aesthetics","author":"Carruthers","year":"2004","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000000357","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines","volume":"41","author":"Carruthers","year":"2015","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/DSS.0000000000000357","article-title":"A multicenter, randomized, double-Blind, placebo-controlled Study to evaluate the efficacy and safety of repeated OnabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines","volume":"41","author":"Carruthers","year":"2015","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0b013e31826538c7","article-title":"Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia","author":"Charles","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2026.109250_bib25","series-title":"Machine Learning and Deep Learning in Real-Time Applications","article-title":"Deep learning with PyTorch","author":"Chaudhary","year":"2020"},{"key":"10.1016\/j.toxicon.2026.109250_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/nau.25370","article-title":"Real-world onabotulinumtoxinA treatment patterns in patients with overactive bladder","volume":"43","author":"Chughtai","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2026.109250_bib27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4103\/IJMR.2010_132_05_489","article-title":"Botulinum toxin: Bioweapon & magic drug","volume":"132","author":"Dhaked","year":"2010","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.toxicon.2026.109250_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/nau.25107","article-title":"Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder","volume":"42","author":"DiCarlo-Meacham","year":"2023","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2026.109250_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2026.109250_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/ene.12393","article-title":"Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine","volume":"21","author":"Diener","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib32","article-title":"The effects of Age, gender, and postvoid residual volume on catheterization rates after treatment with OnabotulinumtoxinA for overactive bladder","volume":"57","author":"Dmochowski","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.toxicon.2026.109250_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxina for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.toxicon.2026.109250_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2012.07.138","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program","volume":"68","author":"Dodick","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418825382","article-title":"Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2026.109250_bib36","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Dom\u00ednguez","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib37","article-title":"Poison to prescription: a history of botulinum toxin in medicine","volume":"103","author":"Dowson","year":"2009","journal-title":"BJU Int."},{"key":"10.1016\/j.toxicon.2026.109250_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-015-1478-1","article-title":"Botulinum toxin drugs: brief history and outlook","author":"Dressler","year":"2016","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2026.109250_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: mechanisms of action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib40","series-title":"Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023 Key Findings Data from the National Health and Nutrition Examination Survey","author":"Emmerich","year":"2024"},{"key":"10.1016\/j.toxicon.2026.109250_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.60.2.151","article-title":"Historical note on the therapeutic use of botulinum toxin in neurological disorders","volume":"60","author":"Erbguth","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2026.109250_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20003","article-title":"Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin","volume":"19","author":"Erbguth","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2026.109250_bib41","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: the chequered history of botulinum toxin","author":"Erbguth","year":"2008","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2026.109250_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2018.03.002","article-title":"Minimal clinically important change in the Toronto Western spasmodic torticollis rating scale","volume":"52","author":"Espay","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2026.109250_bib45","article-title":"Treatment of adult spasticity with botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Esquenazi","year":"2023","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.toxicon.2026.109250_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.06.676","article-title":"Efficacy and safety of 2 doses of onabotulinumtoxin A for the treatment of masseter muscle prominence: 6-Month results from a randomized, phase 2b placebo-controlled study","volume":"87","author":"Fabi","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2026.109250_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/asjof\/ojab036","article-title":"High-dose neuromodulators: a roundtable on making sense of the data in real-world clinical practice","volume":"3","author":"Fabi","year":"2021","journal-title":"Aesthet. Surg. J. Open Forum"},{"key":"10.1016\/j.toxicon.2026.109250_bib48","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/DSS.0000000000001414","article-title":"Forehead line treatment with onabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study","volume":"43","author":"Fagien","year":"2017","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2018.11.080","article-title":"Efficacy and safety of onabotulinumtoxinA for treatment of pediatric upper limb spasticity: primary results","volume":"156","author":"Fehlings","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib50","article-title":"Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal","volume":"33","author":"Ferrari","year":"2018","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib51","doi-asserted-by":"crossref","DOI":"10.2165\/00003495-200262040-00011","article-title":"Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia","author":"Figgitt","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.toxicon.2026.109250_bib52","doi-asserted-by":"crossref","DOI":"10.1007\/s10354-017-0553-7","article-title":"The history of botulinum toxin: from poison to beauty","volume":"167","author":"Fran\u00e7a","year":"2017","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.toxicon.2026.109250_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.12968\/joan.2012.1.2.76","article-title":"Science of botulinum toxin: structure, mechanisms of action and therapeutic uses","volume":"1","author":"Fromage","year":"2012","journal-title":"Journal of Aesthetic Nursing"},{"key":"10.1016\/j.toxicon.2026.109250_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-022-01361-z","article-title":"Drug dosing in children with obesity: a narrative updated review","author":"Gaeta","year":"2022","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.toxicon.2026.109250_bib55","series-title":"Texts in Statistical Science","article-title":"Bayesian data analysis gelman","author":"Gelman","year":"2013"},{"key":"10.1016\/j.toxicon.2026.109250_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.818726","article-title":"Characterizing pharmacokinetics in children with obesity\u2014physiological, drug, patient, and methodological considerations","author":"Gerhart","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.toxicon.2026.109250_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.13160","article-title":"Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?","volume":"83","author":"Germovsek","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxicon.2026.109250_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964935","article-title":"Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings","author":"Germovsek","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.toxicon.2026.109250_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/j.1524-4725.2012.02582.x","article-title":"OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines","volume":"38","author":"Glogau","year":"2012","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib60","doi-asserted-by":"crossref","DOI":"10.1099\/00222615-39-4-243","article-title":"Therapeutic application of botulinum toxin","author":"Hambleton","year":"1993","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.toxicon.2026.109250_bib61","doi-asserted-by":"crossref","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","author":"Hanley","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxicon.2026.109250_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2015.132","article-title":"Drug dosing and pharmacokinetics in children with obesity a systematic review","author":"Harskamp-Van Ginkel","year":"2015","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.toxicon.2026.109250_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2009.09.005","article-title":"The updated european consensus 2009 on the use of botulinum toxin for children with cerebral palsy","author":"Heinen","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21097","article-title":"When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy","author":"Heinen","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2026.109250_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.toxicon.2026.109250_bib66","series-title":"EAI\/springer Innovations in Communication and Computing","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-57077-4_10","article-title":"PyTorch","author":"Imambi","year":"2021"},{"key":"10.1016\/j.toxicon.2026.109250_bib67","doi-asserted-by":"crossref","DOI":"10.1517\/14712598.2014.897322","article-title":"Intradetrusor onabotulinumtoxinA for overactive bladder","author":"Jambusaria","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.toxicon.2026.109250_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.12613","article-title":"Injectable DaxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study","volume":"5","author":"Jankovic","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.toxicon.2026.109250_bib69","article-title":"Treatment of cervical dystonia with botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Jankovic","year":"2023","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.toxicon.2026.109250_bib70","doi-asserted-by":"crossref","DOI":"10.1152\/jappl.2000.89.1.81","article-title":"Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr","volume":"89","author":"Janssen","year":"2000","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.toxicon.2026.109250_bib72","article-title":"Reliable error estimation for sobol\u2019 indices","volume":"28","author":"Jim\u00e9nez Rugama","year":"2018","journal-title":"Stat. Comput."},{"key":"10.1016\/j.toxicon.2026.109250_bib71","article-title":"OnabotulinumtoxinA in overactive bladder: evidence-Based consensus recommendations","author":"Jim\u00e9nez-Cidre","year":"2016","journal-title":"Actas Urol. Esp."},{"key":"10.1016\/j.toxicon.2026.109250_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjac157","article-title":"Safety, pharmacodynamic response, and treatment satisfaction with OnabotulinumtoxinA 40 U, 60 U, and 80 U in subjects with moderate to severe dynamic glabellar lines","volume":"42","author":"Joseph","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"10.1016\/j.toxicon.2026.109250_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/minf.201400137","article-title":"Establishing good computer modelling practice (GCMP) in the prediction of chemical toxicity","volume":"34","author":"Judson","year":"2015","journal-title":"Mol. Inf."},{"key":"10.1016\/j.toxicon.2026.109250_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/00224065.2018.1489042","article-title":"A Bayesian hierarchical model for quantitative and qualitative responses","volume":"50","author":"Kang","year":"2018","journal-title":"J. Qual. Technol."},{"key":"10.1016\/j.toxicon.2026.109250_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000002047","article-title":"Efficacy, patient-reported outcomes, and safety in Male subjects treated with OnabotulinumtoxinA for improvement of moderate to severe horizontal forehead lines","volume":"46","author":"Keaney","year":"2020","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib77","doi-asserted-by":"crossref","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from hull, UK","volume":"15","author":"Khalil","year":"2014","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2026.109250_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/00207450600674525","article-title":"Central effect of botulinum toxin type A in humans","author":"Kim","year":"2006","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.toxicon.2026.109250_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/PRS.0b013e3181d0ad03","article-title":"Botulinum toxin type a for the treatment of hypertrophy of the masseter muscle","volume":"125","author":"Kim","year":"2010","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9120403","article-title":"Botulinum toxin in the field of dermatology: novel indications","author":"Kim","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib81","doi-asserted-by":"crossref","DOI":"10.1007\/s00192-021-05030-3","article-title":"Treatment of refractory overactive bladder with OnabotulinumtoxinA vs PTNS: TROOP trial","volume":"33","author":"Kopcsay","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.toxicon.2026.109250_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2017.11.010","article-title":"Botulinum toxin: central or peripheral mechanism of action?","volume":"46","author":"Lackovic","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2026.109250_bib83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.baga.2017.06.001","article-title":"Systematic analysis of botulinum neurotoxin type A immunogenicity in clinical studies","volume":"9","author":"Lacroix-Desmazes","year":"2017","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.toxicon.2026.109250_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221123058","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data","author":"Lanteri-Minet","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2026.109250_bib85","doi-asserted-by":"crossref","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.toxicon.2026.109250_bib87","article-title":"Treatment of hyperhidrosis with botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Lowe","year":"2023","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.toxicon.2026.109250_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2007.01.009","article-title":"Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety","author":"Lowe","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2026.109250_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2016.10.026","article-title":"Management of overactive bladder with OnabotulinumtoxinA: systematic review and meta-analysis","volume":"100","author":"L\u00f3pez Ramos","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.toxicon.2026.109250_bib89","doi-asserted-by":"crossref","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.toxicon.2026.109250_bib90","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-91","article-title":"Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia","volume":"14","author":"Marsh","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13020120","article-title":"Therapeutic use of botulinum neurotoxins in dermatology: systematic review","author":"Martina","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2014.06.001","article-title":"Botulinum toxin A, brain and pain","author":"Matak","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.toxicon.2026.109250_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.rehab.2019.03.004","article-title":"Immunogenicity induced by botulinum toxin injections for limb spasticity: a systematic review","author":"Mathevon","year":"2019","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"10.1016\/j.toxicon.2026.109250_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2018.17977","article-title":"Bayesian hierarchical models","author":"McGlothlin","year":"2018","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.toxicon.2026.109250_bib95","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxina for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib96","doi-asserted-by":"crossref","DOI":"10.1517\/17425255.2011.570331","article-title":"The effects of obesity on drug pharmacokinetics in humans","author":"Morrish","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.toxicon.2026.109250_bib97","article-title":"Diffusion tensor MR imaging and fiber tractography: technical considerations","author":"Mukherjee","year":"2008","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.toxicon.2026.109250_bib98","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-13-118","article-title":"OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review","volume":"13","author":"Nalysnyk","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib99","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2026.109250_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.323.7313.596","article-title":"Botulinum toxin type a in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial","author":"Naumann","year":"2001","journal-title":"Br. Med. J."},{"key":"10.1016\/j.toxicon.2026.109250_bib101","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.139.6.731","article-title":"Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study","author":"Naumann","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.toxicon.2026.109250_bib102","article-title":"Treatment of neurogenic detrusor overactivity and overactive bladder with botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Nitti","year":"2023","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.toxicon.2026.109250_bib103","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.toxicon.2026.109250_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2021.106584","article-title":"Explanation of machine learning models using shapley additive explanation and application for real data in hospital","volume":"214","author":"Nohara","year":"2022","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.toxicon.2026.109250_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.envsoft.2011.08.010","article-title":"Sobol\u2019 sensitivity analysis of a complex environmental model","volume":"26","author":"Nossent","year":"2011","journal-title":"Environ. Modell. Software"},{"key":"10.1016\/j.toxicon.2026.109250_bib106","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v074.i11","article-title":"Synthpop: bespoke creation of synthetic data in R","volume":"74","author":"Nowok","year":"2016","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.toxicon.2026.109250_bib107","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000001779","article-title":"OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from a phase 3 double-blind study","volume":"45","author":"Ogilvie","year":"2019","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib108","doi-asserted-by":"crossref","DOI":"10.1007\/s40122-021-00328-y","article-title":"Is there a gender difference in the response to onabotulinumtoxinA in chronic migraine? Insights from a real-life European multicenter study on 2879 patients","volume":"10","author":"Ornello","year":"2021","journal-title":"Pain Ther."},{"key":"10.1016\/j.toxicon.2026.109250_bib109","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3121\/cmr.2007.716","article-title":"Botulinum toxin in poststroke spasticity","volume":"5","author":"Ozcakir","year":"2007","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.toxicon.2026.109250_bib110","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000002216","article-title":"Efficacy, patient-reported outcomes, and safety for millennial subjects treated with OnabotulinumtoxinA for moderate to severe horizontal forehead lines","volume":"46","author":"Palm","year":"2020","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/toxins5030524","article-title":"Safety of botulinum toxin a in children and adolescents with cerebral palsy in a pragmatic setting","volume":"5","author":"Papavasiliou","year":"2013","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10060224","article-title":"Botulinum toxin for central neuropathic pain","author":"Park","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib113","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41597-022-01833-1","article-title":"TractoInferno - a large-scale, open-source, multi-site database for machine learning dMRI tractography","volume":"9","author":"Poulin","year":"2022","journal-title":"Sci. Data"},{"key":"10.1016\/j.toxicon.2026.109250_bib114","article-title":"Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications","author":"Rahman","year":"2021","journal-title":"Aesthet. Surg. J."},{"key":"10.1016\/j.toxicon.2026.109250_bib115","doi-asserted-by":"crossref","DOI":"10.1097\/PRS.0000000000008904","article-title":"Botulinum toxin type A immunogenicity across multiple indications: an overview systematic review","author":"Rahman","year":"2022","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108560","article-title":"Targeting the glabellar frown lines with OnabotulinumtoxinA: in-Silico evidence supporting concentrated, low-volume injection protocols","volume":"267","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108548","article-title":"In silico multiscale computational modelling of botulinum toxin A diffusion for glabellar wrinkle treatment: optimizing injection volumes across formulations","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib119","article-title":"Predictive modelling of immunogenicity to botulinumtoxin A treatments for glabellar lines","author":"Rahman","year":"2024","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108665","article-title":"Computational model-informed comparative evaluation of botulinum toxin a formulations: a 20-year simulation of onset, diffusion, duration, and immunogenicity","volume":"269","author":"Rahman","year":"2026","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib121","article-title":"If accessory proteins dissociate, why don't toxins behave the same? Multiscale simulation shows divergent in silico profiles despite an identical core neurotoxin","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib122","article-title":"Excipient substitution in botulinum toxin type A formulations: insights from multi-scale in silico modelling","author":"Rahman","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxicon.2026.109250_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108946","article-title":"Beyond structural divergence: multiscale computational immunogenicity modelling of botulinum neurotoxin E and cross-reactivity in botulinum neurotoxin A primed hosts","volume":"271","author":"Rahman","year":"2026","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib124","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/toxins17100498","article-title":"Computational modelling suggests bacteriostatic saline does not reverse botulinum toxin-induced brow ptosis","volume":"17","author":"Rahman","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00238-025-02311-8","article-title":"In silico multiscale comparison of LetibotulinumtoxinA and OnabotulinumtoxinA in glabellar line treatment: diffusion dynamics, receptor affinity, and immunologic clearance","volume":"48","author":"Rahman","year":"2025","journal-title":"Eur. J. Plast. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/toxins17040182","article-title":"Computational immunogenetic analysis of botulinum toxin A immunogenicity and HLA gene haplotypes: new insights","volume":"17","author":"Rahman","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib127","doi-asserted-by":"crossref","DOI":"10.1007\/s00266-026-05700-x","article-title":"Challenging interchangeability: dynamic dose-response modelling of botulinum toxin A products","author":"Rahman","year":"2026","journal-title":"Aesthetic Plast. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib116","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/DSS.0000000000004293","article-title":"Immunogenicity of botulinum toxin A: insights","volume":"50","author":"Rahman","year":"2024","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia","author":"Ramirez-Castaneda","year":"2013","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib129","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/DSS.0000000000000424","article-title":"Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure","volume":"41","author":"Rivers","year":"2015","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2026.109250_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.toxicon.2026.109250_bib132","article-title":"Management of spasticity with onabotulinumtoxinA: practical guidance based on the Italian real-life post-stroke spasticity survey","volume":"33","author":"Sandrini","year":"2018","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.toxicon.2026.109250_bib133","article-title":"Nonparametric regression using deep neural networks with relu activation function","volume":"48","author":"Schmidt-Hieber","year":"2020","journal-title":"Ann. Stat."},{"key":"10.1016\/j.toxicon.2026.109250_bib134","doi-asserted-by":"crossref","DOI":"10.1097\/00002508-200211001-00002","article-title":"Therapeutic use of botulinum toxins: background and history","author":"Setler","year":"2002","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.toxicon.2026.109250_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082126","article-title":"Endoscopic intragastric injection of botulinum toxin A in Obese patients accelerates weight loss after bariatric surgery: follow-up of a randomised controlled trial (intraTox study)","volume":"11","author":"S\u00e1nchez-Torralvo","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.toxicon.2026.109250_bib135","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjac210","article-title":"PrabotulinumtoxinA vs OnabotulinumtoxinA for the treatment of adult males with moderate to severe glabellar lines: post-Hoc analyses of the phase III clinical study data","volume":"42","author":"Solish","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"10.1016\/j.toxicon.2026.109250_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2003.12.040","article-title":"US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey","volume":"51","author":"Strutton","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2026.109250_bib137","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjaf204","article-title":"OnabotulinumtoxinA treatment for masseter muscle prominence: 6-month safety and efficacy results, including patient-reported outcomes, from a phase 3, randomized, placebo-controlled, multiregional trial","volume":"46","author":"Sun","year":"2026","journal-title":"Aesthet. Surg. J."},{"key":"10.1016\/j.toxicon.2026.109250_bib138","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-015-1125-7","article-title":"The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis","author":"Sun","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.toxicon.2026.109250_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/toxins7072659","article-title":"Treatment of chronic migraine with OnabotulinumtoxinA: mode of action, efficacy and safety","author":"Szok","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib140","article-title":"Study finds botulinum toxin spreads to CNS tissue in mice","volume":"8","author":"Talan","year":"2008","journal-title":"Neurol. Today"},{"key":"10.1016\/j.toxicon.2026.109250_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2012.11.011","article-title":"Botulinum neurotoxins: mechanism of action","author":"Tighe","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109250_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.pmrj.2017.12.006","article-title":"OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: a randomized trial","author":"Wein","year":"2018","journal-title":"PM and R"},{"key":"10.1016\/j.toxicon.2026.109250_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11010021","article-title":"Central effects of botulinum Neurotoxin\u2014Evidence from human studies","author":"Weise","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109250_bib144","first-page":"276","article-title":"A general model for the origin of allometric scaling laws in biology","author":"West","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.toxicon.2026.109250_bib145","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20012","article-title":"Pharmacokinetic properties of different formulations of botulinum neurotoxin type A","volume":"19","author":"Wohlfarth","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2026.109250_bib146","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-022-02742-x","article-title":"OnabotulinumtoxinA in chronic migraine: is the response dose dependent?","volume":"22","author":"Zandieh","year":"2022","journal-title":"BMC Neurol."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010126002680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010126002680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:56:12Z","timestamp":1788458172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010126002680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":146,"alternative-id":["S0041010126002680"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2026.109250","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From uniformity to individuality: Computational modelling provides a mechanistic rationale for weight-adjusted botulinum neurotoxin a dosing","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2026.109250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109250"}}